Monoamine Oxidase Inhibitor
38 drugs across 21 manufacturers|31 Generic,7 Brand
The Monoamine Oxidase Inhibitor class contains 38 NDCs from 21 manufacturers (31 generic, 7 brand), at an average NADAC of $10.64 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
38
31G / 7B
Manufacturers
21
Avg $10.6400/unit
Avg 7d Change
+0.87%
Across 30 drugs with changes
7d Activity
of 38 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
21 manufacturers producing drugs in this therapeutic class(4 pricing outliers)
and 9 more manufacturers
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Apotex Corp. manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Rasagiline market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Monoamine Oxidase Inhibitor class?
The Monoamine Oxidase Inhibitor class contains 38 NDCs from 21 manufacturers — 31 generic and 7 brand products.
What is the average price of Monoamine Oxidase Inhibitor drugs?
The average NADAC for the Monoamine Oxidase Inhibitor class is $10.6400 per unit across 38 NDCs.
Is generic cheaper than brand in the Monoamine Oxidase Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $0.6928, versus $54.6919 for brand — brand products average about 79× the generic price.
Which manufacturers make Monoamine Oxidase Inhibitor drugs?
21 manufacturers make drugs in the Monoamine Oxidase Inhibitor class. Ranked by number of NDCs, the largest are Apotex Corp. (4), Viatris Specialty LLC (3), Novitium Pharma LLC (3), Teva Neuroscience, Inc. (2), Teva Pharmaceuticals USA Inc. (2).
How has Monoamine Oxidase Inhibitor pricing changed recently?
Over the past 7 days, 18 NDCs in this class rose and 12 fell, with a class-wide average change of +0.9%.